| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | glycoprotein CD28 |
| Clinical data | |
| Other names | BMS-931699 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C552H859N149O164S4 |
| Molar mass | 12335.06 g·mol |
Lulizumab pegol (INN; development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases.
This drug was developed by Bristol-Myers Squibb.
References
- World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |